EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, XNCR: Xencor Inc

27 Oct 25 12:30
LAST:

14.43

CHANGE:
 1.22		OPEN:
13.47		HIGH:
14.64		ASK:
1.00		VOLUME:
473.7K
CHG(%):
9.24		PREV:
13.21		LOW:
13.28		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
27 Oct 2513.4714.6413.2814.43473.7K
24 Oct 2512.4714.2012.3013.211.56M
23 Oct 2513.2513.2912.1712.341.29M
22 Oct 2514.5114.5913.2713.291.89M
21 Oct 2515.0715.3414.2814.511.16M
20 Oct 2514.9415.6914.6015.072.01M
17 Oct 2514.8515.0714.4714.771.94M
16 Oct 2514.4015.3714.3814.953.19M
15 Oct 2512.5814.2512.4714.101.41M
14 Oct 2513.9513.9811.1712.432.9M

COMPANY PROFILE

Name:Xencor Inc
About:Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
Sector:Healthcare
Industry:Biotechnology
Address:465 North Halstead Street, Pasadena, CA, United States, 91107
Website:https://www.xencor.com
CUSIP:98401F105
CIK:0001326732
ISIN:US98401F1057
FIGI:BBG0026ZG4W0

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:13.566.4%
MA10:13.913.7%
MA20:13.139.9%
MA50:10.5736.5%
MA100:9.5651.0%
MA200:11.0530.6%
STO9:62.48
STO14:62.48
RSI14:60.58 
WPR14:-23.44
MTM14:2.03
ROC14:0.16 
ATR:1.27 
Week High:15.698.7%
Week Low:12.1718.6%
Month High:15.698.7%
Month Low:11.1730.6%
Year High:27.2488.8%
Year Low:6.92108.5%